| Patent application number | Description | Published |
|---|
| 20080207499 | Rage-related methods for treating and preventing diabetic retinopathy - This invention provides a method for treating diabetic retinopathy in a subject afflicted therewith, comprising administering to the subject's eyes a therapeutically effective amount of soluble RAGE or a derivative thereof, thereby treating diabetic retinopathy in the subject. This invention further provides a method for inhibiting the onset of diabetic retinopathy in a subject afflicted therewith, comprising administering a prophylactically effective amount of soluble RAGE or a derivative thereof to the subject's eyes, thereby inhibiting the onset of diabetic retinopathy in the subject. | 08-28-2008 |
| 20080214453 | Methods for treating inflammation - The present invention provides a method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) in an amount effective to inhibit binding of advanced glycation endproducts (AGEs) to RAGE thereby treating inflammation in the subject. The present invention also provides for a method for treating inflammation in a subject which comprises administering to the subject an agent in an amount effective to inhibit the interaction between receptor for advanced glycation endproduct (RAGE) and its ligand thereby treating inflammation in the subject. | 09-04-2008 |
| 20090028882 | Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof - This invention provides a method of inhibiting the binding of beta-sheet fibril to RAGE on the surface of a cell which comprises contacting the cell with a binding-inhibiting amount of a compound capable of inhibiting binding of beta-sheet fibril to RAGE so as to thereby inhibit binding of beta-sheet fibril to RAGE. | 01-29-2009 |
| 20090060925 | Rage Fusion Proteins and Methods of Use - Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies. | 03-05-2009 |
| 20090220484 | Rage/Diaphanous Interaction and Related Compositions and Methods - This invention provides a polypeptide consisting essentially of all or a portion of the cytoplasmic domain of RAGE. This invention further provides a polypeptide consisting essentially of a portion of Diaphanous that binds to the cytoplasmic domain of RAGE. Additionally, this invention provides related nucleic acids, vectors, cells and methods. | 09-03-2009 |
| 20100254983 | USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES - This invention provides a method for treating obesity in which comprises administering to the subject an antagonist of a receptor for advanced glycation end products (RAGE) in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat obesity in the subject. The present invention also provides a method for treating hyperglycemia and increased cholesterol, insulin, triglyceride and leptin levels comprising administering to the subject an antagonist of RAGE in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat hyperglycemia and lower cholesterol, insulin, triglyceride and leptin levels on the subject. | 10-07-2010 |
| 20100255081 | Method for treating symptoms of diabetes - The present invention provides a method for treating symptoms of diabetes in a diabetic subject which comprises administering to the subject a therapeutically effective amount of an agent which inhibits binding of advanced glycation endproducts to any receptor for advanced glycation endproducts so as to treat chronic symptoms of diabetes in the subject. | 10-07-2010 |
| 20100292134 | Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury - This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels. The invention also provides a method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to prevent exaggerated restenosis in the subject. | 11-18-2010 |
| 20110126298 | Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (RAGE) In Brain And Uses Thereof - The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence. | 05-26-2011 |
